Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Soluble CTLA4 mutant molecules and uses thereof

A technology of nucleic acid molecules and carriers, applied in the field of soluble CTLA4 molecules, which can solve problems such as the influence of affinity

Inactive Publication Date: 2008-09-03
BRISTOL MYERS SQUIBB CO
View PDF7 Cites 8 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Therefore, it was determined that the MYPPPY motif of CTLA4 and CD28 is important for binding to CD80, but certain non-conserved amino acid residues in the CDR1-like region and CDR3-like region of CTLA4 also contribute to the enhancement of the binding affinity of CTLA4 to CD80
[0014] Shows that CTLA4Ig effectively blocks CD80-associated T cell co-stimulation, but not as effectively as when blocking CD86-associated responses

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Soluble CTLA4 mutant molecules and uses thereof
  • Soluble CTLA4 mutant molecules and uses thereof
  • Soluble CTLA4 mutant molecules and uses thereof

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0117] This example provides an illustration of the method used to generate a nucleotide sequence encoding a soluble CTLA4 mutant molecule of the invention. Single point mutant L104EIg was generated and tested for binding kinetics to CD80 and / or CD86. The L104EIg nucleotide sequence was used as a template to generate the double-site mutant CTLA4 sequence-L104EA29YIg, and the binding kinetics of L104EA29YIg to CD80 and / or CD86 was tested.

[0118] CTLA4Ig codon-based mutagenesis :

[0119] A mutagenesis and screening strategy was developed to identify mutant CTLA4Ig molecules with slower dissociation rates ("off" rates) from CD80 and / or CD86 molecules. Single point mutant nucleotide sequences were generated using CTLA4Ig (US Patent Nos. 5,844,095, 5,851,795, and 5,885,796; ATCC Deposit No. 68629) as a template. Designed for random mutagenesis of specific cDNA codons by allowing any base in codon positions 1 and 2, but only guanine and thymine in position 3 (XXG / T; also know...

Embodiment 2

[0122] A description of the screening methods used to identify the single-site and double-site mutant CTLA4 polypeptides expressed from the constructs described in Example 1, wherein the mutant CTLA4 polypeptides exhibit binding affinity for the CD80 and CD86 antigens, is provided below Higher than non-mutated CTLA4Ig molecules.

[0123] Current in vitro and in vivo studies demonstrate that CTLA4Ig by itself cannot completely block the priming of antigen-specific activated T cells. In vitro studies measuring inhibition of T cell proliferation using CTLA4Ig and CD80 or CD86 specific monoclonal antibodies showed that anti-CD80 monoclonal antibodies did not enhance CTLA4Ig inhibition. Anti-CD86 monoclonal antibodies, however, enhanced the inhibition, suggesting that CTLA4Ig was not as effective in blocking CD86 interactions. These data support the earlier findings of Linsley et al. ( Immunity, (1994), 1:793-801), the finding that inhibition of CD80-mediated cellular responses ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The present invention provides soluble CTLA4 mutant molecules which bind with greater avidity to the CD80 and / or CD86 antigen than wild type CTLA4 or non-mutated CTLA4Ig. The soluble CTLA4 molecules have a first amino acid sequence comprising the extracellular domain of CTLA4, where certain amino acid residues within the S25-R33 region and M97-G107 region are mutated. The mutant molecules of the invention may also include a second amino acid sequence which increases the solubility of the mutant molecule.

Description

[0001] This application is a divisional application of the following applications: filing date: May 23, 2001; application number: 01810145.3 (PCT / US01 / 17139); invention title: "soluble CTLA4 mutant molecule and its application". [0002] Various publications are cited throughout this application. The disclosures of these publications in their entirety are incorporated by reference into this application in order to more fully describe the state of the art to which this invention pertains. field of invention [0003] The present invention relates to the field of soluble CTLA4 molecules mutated from wild-type CTLA4 to retain the ability to bind CD80 and / or CD86. Background of the invention [0004] Antigen-nonspecific intercellular interactions between T lymphocytes and antigen-presenting cells (APCs) generate T-cell co-stimulatory signals that elicit T-cell responses against antigens (Jenkins and Johnson (1993) Curr. Opin. Immunol. 5:361-367). Costimulatory signals determine...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): C07K14/705C12N15/12C12N15/63C12N15/70C12N15/79A61K38/16A61P37/02C12N15/09A61K38/00A61K45/00A61P37/00A61P37/06C07KC07K14/47C07K16/00C07K19/00C12N5/10C12P21/02C12Q1/02G01N33/68
CPCG01N33/502G01N33/5005A61K38/00G01N33/5008C07K14/70521G01N33/68G01N33/505C07K2319/30A61P37/00A61P37/02A61P37/06C07K14/705
Inventor R·J·皮奇J·R·奈穆拉P·S·林斯利J·巴约拉斯
Owner BRISTOL MYERS SQUIBB CO
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com